Genmab bulks ADC pipeline with $1.8-billion purchase of ProfoundBio

03 Apr 2024
Drug ApprovalADCPhase 2AcquisitionPhase 1
Genmab continued to expand its presence in the antibody-drug conjugate (ADC) field with a deal to buy ProfoundBio for $1.8 billion in cash. The transaction will give Genmab three clinical programmes, including the FRα-targeted, Topo1 ADC rinatabart sesutecan (Rina-S).
The therapy, also known as PRO1184, is currently in Phase II development for the treatment of ovarian cancer and other FRα-expressing solid tumoursFRα-expressing solid tumours. ProfoundBio’s pipeline also includes the CD70-targeted ADC PRO1160 and another dubbed PRO1107 that targets PTK7.
Jan van de Winkel, CEO of Genmab, noted that the purchase “firmly aligns with our long-term strategy,” adding that “ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition.” The transaction is expected to close this quarter.
Genmab already has an ADC partnership with Seagen, which produced the drug Tivdak (tisotumab vedotin-tftv) approved by the FDA in 2021 as a treatment for cervical cancer. The company also has a collaboration with ADC Therapeutics and another agreement with Synaffix for its ADC technologies.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.